di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate) CAS: 1007882-23-6
| Product Parameters | |
|---|---|
| Catalog No. | BK33YL |
| CAS.RN | 1007882-23-6 |
| Molecular Formula | C36H44N6O4 |
| Molecular Weight | 624.77 g/mol |
| Purity | NLT 98% |
Product Overview
Daclatasvir Intermediate II is a high-purity pharmaceutical intermediate primarily used in the synthesis of the antiviral drug daclatasvir, participating as a key structural unit in molecular construction. This product is suitable for small-scale, pilot-scale, and industrial-scale production in the drug development stage. It possesses excellent chemical stability and reactivity, and can be widely applied in innovative drug development and custom synthesis of active pharmaceutical ingredients, meeting the stringent requirements of pharmaceutical companies for high-quality intermediates.
Applications
- Synthetic precursors for the antiviral drug daclatasvir
- Customized synthesis project of pharmaceutical intermediates
- Drug molecular structure optimization research
- Supply of key intermediates in innovative drug development
- Development and optimization of active pharmaceutical ingredient process routes
Quality & Supply Capability
English Name: di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate) Properties: This product is an organic compound containing a diimidazole group and a piperidine carboxylic acid ester structure. It has high thermal stability and chemical inertness, is readily soluble in common organic solvents, and is suitable for use in various synthetic routes. Storage Recommendations: Store in a sealed, light-protected, and dry place, subject to the specific COA/MSDS. Supply Capabilities: Samples, gram-level, kilogram-level, commercial batches. Packaging Specifications: Aluminum foil bags, fluorinated bottles, cardboard drums, customized packaging. Documentation Support: COA, MSDS, HPLC, NMR, etc. We provide a full-process service from laboratory sample supply to small-scale preparation, pilot-scale amplification, and customized batch production. We can flexibly adjust purity standards, impurity control ranges, packaging specifications, and delivery cycles according to customer needs, while providing complete quality documentation support. We also provide comprehensive technical support from the early stages of R&D to industrial production, helping clients achieve process development, route optimization, and project transformation, ensuring efficient and compliant project progress.
Why Choose Bioncan
Focused on pharmaceutical intermediates, possessing extensive synthesis experience and technological expertise. Full-scale supply capability, covering all stages from laboratory to commercial production. Provides complete quality control documentation to meet international pharmaceutical regulatory requirements. Supports customized needs, offering structural modifications or process adjustments based on specific customer requirements. Supports process optimization technologies to help customers improve synthesis efficiency and product quality.
Intermediates of Daclatasvir
| Catalog No. | Product Name | CAS |
|---|---|---|
| BA48B5 | Daclatasvir API | 1009119-64-5 |
| BK94B1 | Daclatasvir dihydrochloride | 1009119-65-6 |
| BK76B8 | 4,4'-Bis(2-bromoacetyl)biphenyl | 4072-67-7 |
| BK33YL | di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate) | 1007882-23-6 |
| BK8QE9 | 2-((2S)-Pyrrolidin-2-yl)-5-(4-(4-(2- ((2S)-pyrrolidin-2-yl)-1H-imidazol -5-yl)phenyl)phenyl)-1himidazole tetrahydrochloride | 1009119-83-8 |
Customers are responsible for ensuring compliance with applicable patent, regulatory, and import/export requirements in their respective jurisdictions.
Online Consulting
For quotation, inventory, samples, COA, MSDS, or custom synthesis support for CAS 1007882-23-6, please submit your requirements. We will respond according to purity, quantity, delivery timeline, and documentation needs.
